MedPath

Effect of chromium on diabetes mellitus type2 treatment

Phase 2
Conditions
Diabetes.
Diabetes mellitus
E10, E11,
Registration Number
IRCT2013012812311N1
Lead Sponsor
Private
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

1. HbA1c=10%, HbA1c=7%; 2. DM2; 3. BMI=35, BMI=25; 4. Stability of antidiabetic treatment during recent 3 mounths; 5. Age 30-65 years. Exclusion criteria: 1. Cr?1.5 (men), Cr>1.4 (female); 2. Liver function test (ALT, AST) >2 fold of upper limit normal; 3. Pregnancy; 4. Heart Failure; 5. Chronic Liver disease; 6. Uncontrolled hypertension; 7. Immunosupression disease and immunosupresive therapy; 8. Alcohol use and other drug abuse; 9. Psychological unhealthy; 10. Confined to bed during recent 1 years.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ric acid. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HbA1c. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;LDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;TG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;FPG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BS 2hpp. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BMI. Timepoint: Before intervension & 3 months later. Method of measurement: kg/m2.;Creatinine. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath